Product Images Rivaroxaban

The text provides information about Rivaroxaban Tablets, USP with a strength of 2.5 mg per tablet. It includes details about the manufacturer, batch number, expiration date, and storage instructions. The package is meant for hospital use only, containing 60 tablets in unit dose blister cards. The medication guide for patients is available online.*

This is a statistical breakdown of a study comparing patients on Warfarin to those on Rivaroxaban. The data includes information on different patient groups based on age, gender, weight, medical history (prior stroke/TIA, diabetic status), CHADS2 score, creatinine clearance, geographic region, and ASA usage. The study also provides events per year for each medication group, as well as Hazard Ratios and 95% Confidence Intervals. It appears that some parameters favor Rivaroxaban while others favor Warfarin, as indicated by the Hazard Ratio values.*

Population Description - PK Fold Change and 30% CI. This information relates to the end stage renal disease population, including aspects such as renal impairment, age group, body weight, and hepatic impairment. The document discusses specific parameters and factors related to medical conditions in the study population.*

This appears to be a comparison between the medication Rivaroxaban and a placebo, showing the cumulative incidence rate over a period of time and the hazard ratio with a confidence interval. The data includes the number of subjects at risk for each group and the days from randomization. This information is likely part of a clinical trial report evaluating the effectiveness of Rivaroxaban.*

This data presents treatment outcomes based on various factors such as age, sex, weight, eGFR, baseline diabetes, and other medical conditions. The study compares the efficacy of Rivaroxaban and Placebo in preventing certain health events. Rivaroxaban had a lower percentage of outcomes in most categories compared to Placebo. The values are expressed as n/N (%lyear). The Hazard Ratios (HR) with 95% Confidence Intervals (CI) show the effect size of Rivaroxaban compared to Placebo, with values less than 1 indicating that Rivaroxaban is more effective. Available information includes the demographics of the participants and the outcomes of interest.*

The provided text is an evaluation of a study comparing the efficacy outcome (composite of stroke, MI, or cardiovascular death) of a medication called Rivaroxaban versus a placebo. The study includes data categorized by age, sex, region, weight, eGFR, medical history (such as MI history, stroke history, heart failure, diabetes, and PAD), and outcomes for both Rivaroxaban and Placebo groups. Additionally, it provides statistical measures like hazard ratios and confidence intervals showing the effectiveness of Rivaroxaban compared to Placebo.*

This text provides information about a medication called MACLEODY in tablet form, with each tablet containing 2.5 mg of rivaroxaban. It includes details such as the NDC number, storage instructions, and a reminder to keep them out of reach of children. It also references a website for the Medication Guide and lists the manufacturing companies. The full prescribing information can be found in the package insert.*